Abstracts tagged "Economics"

Abstract Number: 0240 • ACR Convergence 2021
Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Joseph Merola¹, Feifei Yang², Natalie Dennis³, Steven Peterson⁴, Iris Lin², Yiting Wang⁵, Soumya Chakravarty⁶, Arthur Quenéchdu³, May Shawi⁷, Claire Fischer³ and Elaine Husni⁸, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). The objectives of this study…
Abstract Number: 0357 • ACR Convergence 2021
Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…
Abstract Number: 0424 • ACR Convergence 2021
Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)
Christopher Bell¹, Juliana Meyers² and Mayank Ajmera², ¹GlaxoSmithKline, Research Triangle Park, NC, ²RTI-Health Solutions, Research Triangle Park, NC
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests…
Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Patompong Ungprasert¹, Thanat Chaikijurajai², Karn Wijarnpreecha³ and Paul Kroner³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
Abstract Number: 0881 • ACR Convergence 2021
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Ann Clarke¹, John Hanly², Yvan St.Pierre³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Juanita Romero-Diaz⁶, Jorge Sanchez-Guerrero⁷, Sasha Bernatsky⁸, Daniel Wallace⁹, David Isenberg¹⁰, Anisur Rahman¹¹, Joan Merrill¹², Paul R Fortin¹³, Dafna Gladman¹⁴, Murray Urowitz¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jnsen²², Graciela Alarcn²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³ and Vernon Farewell³⁴, ¹University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Hanyang University Medical Center, Seoul, Republic of Korea, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ⁸McGill University, Montréal, QC, Canada, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹University College London, London, United Kingdom, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Allegheny Health Network, Wexford, PA, ²²Lund University, Lund, Sweden, ²³University of Alabama at Birmingham, Birmingham, AL, ²⁴Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1076 • ACR Convergence 2021
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
Fiona Koster¹, Deirisa Lopes Barreto², Marc Kok³ and Angelique Weel-Koenders¹, ¹Maasstad Hospital Rotterdam, Rotterdam, Netherlands, ²Maasstad Hospital Rotterdam, Rotterdam, ³Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Transparency and management of healthcare costs is warranted for rheumatoid arthritis (RA) as the disease places a great economic burden on a patient and…
Abstract Number: 1118 • ACR Convergence 2021
The Association of Hand OA with Paid an Unpaid Work Impairment and Related Costs: The Hand Osteoarthritis in Secondary Care Cohort
Sietse Terpstra¹, Lotte van de Stadt¹, Annelies Boonen², Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands
Background/Purpose: Rheumatic musculoskeletal diseases (RMDs) can cause impairment at paid and unpaid work and contributes to societal burden and costs. However, data on this topic…
Abstract Number: 1852 • ACR Convergence 2021
Healthcare Utilization and Economic Burden in Systemic Sclerosis
Leonardo Martin Calderon¹, Mitali Chaudhary¹ and Janet Pope², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
Abstract Number: 0239 • ACR Convergence 2021
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Elaine Husni¹, Steven Peterson², Natalie Dennis³, Feifei Yang⁴, Iris Lin⁴, Yiting Wang⁵, Soumya Chakravarty⁶, Claire Fischer³, May Shawi⁷, Arthur Quenéchdu³ and Joseph Merola⁸, ¹Cleveland Clinic, Cleveland, OH, ²Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…
Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Peter Hur⁵, Nina Kim⁶ and Kaleb Michaud⁷, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁷FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…
Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Shirley Huang¹, Xintong Li², Joehl Nguyen², Jacob Robinson², Susan Hogan³, Vimal Derebail³ and Carolyn Thorpe², ¹University of North Carolina at Chapel Hill, Chapel Hill, ²University of North Carolina Eshelman School of Pharmacy, Chapel Hill, ³University of North Carolina Kidney Center, Chapel Hill
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Cesar Galan¹, Alan Puric², Guy Cozzi², Michele Hamburger³, Elisea Avalos-Reyes⁴ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Northbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
Abstract Number: 0581 • ACR Convergence 2020
A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
Jacquelyn Chou¹, Ervant Maksabedian², David Collier³ and Howard Thom⁴, ¹PRECISION heor, Los Angeles, CA, ²Amgen Inc., LOS ANGELES, CA, ³Amgen, Thousand Oaks, CA, ⁴University of Bristol, Bristol, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].